Short Interest Worth Mentioning: What Will Happen to Derma Sciences DE (NASDAQ:DSCI) Next? The Stock Has Decline in Shorts

December 1, 2016 - By Ellis Scott   ·   0 Comments

Short Interest Worth Mentioning: What Will Happen to Derma Sciences DE (NASDAQ:DSCI) Next? The Stock Has Decline in Shorts

The stock of Derma Sciences DE (NASDAQ:DSCI) registered a decrease of 6.59% in short interest. DSCI’s total short interest was 112,000 shares in December as published by FINRA. Its down 6.59% from 119,900 shares, reported previously. With 29,500 shares average volume, it will take short sellers 4 days to cover their DSCI’s short positions. The short interest to Derma Sciences DE’s float is 0.55%. The stock last traded at $4.8 per share. It is up 34.45% since April 28, 2016 and is uptrending. It has outperformed by 28.53% the S&P500.

Derma Sciences, Inc. is a medical device company. The company has a market cap of $141.59 million. The Firm operates through two divisions: advanced wound care and traditional wound care products. It currently has negative earnings. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.64, from 0.68 in 2016Q1. The ratio increased, as 7 funds sold all Derma Sciences Inc shares owned while 18 reduced positions. 7 funds bought stakes while 10 increased positions. They now own 17.29 million shares or 5.94% less from 18.38 million shares in 2016Q1.
Citigroup has 0% invested in the company for 15 shares. Blackrock Gru last reported 0% of its portfolio in the stock. Blackrock Advsrs Ltd Liability Company accumulated 0% or 2,182 shares. Goldman Sachs last reported 0% of its portfolio in the stock. The Massachusetts-based Adage Prtnrs Group Lc has invested 0% in Derma Sciences Inc (NASDAQ:DSCI). Baker Bros Advsr Limited Partnership has 3.75 million shares for 0.16% of their US portfolio. Dafna Mngmt Limited Co accumulated 1.1% or 353,718 shares. Blackrock Institutional Trust Na last reported 153,052 shares in the company. Franklin Resources accumulated 2.68 million shares or 0.01% of the stock. The United Kingdom-based Barclays Plc has invested 0% in Derma Sciences Inc (NASDAQ:DSCI). C M Bidwell & Associates Ltd holds 0.02% or 22,865 shares in its portfolio. Jacobs Levy Equity Mngmt last reported 92,372 shares in the company. The New York-based Renaissance Techs Limited Liability Co has invested 0% in Derma Sciences Inc (NASDAQ:DSCI). State Street Corporation holds 0% or 11,858 shares in its portfolio. Valley Advisers Incorporated holds 0.01% or 5,000 shares in its portfolio.

Derma Sciences Inc (NASDAQ:DSCI) Ratings Coverage

Out of 4 analysts covering Derma Sciences (NASDAQ:DSCI), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Derma Sciences has been the topic of 6 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Derma Sciences Inc (NASDAQ:DSCI) earned “Neutral” rating by Piper Jaffray on Tuesday, August 11. The company was maintained on Thursday, December 3 by TH Capital. Oppenheimer maintained Derma Sciences Inc (NASDAQ:DSCI) rating on Friday, November 13. Oppenheimer has “Outperform” rating and $8 price target. The rating was maintained by Oppenheimer on Friday, January 8 with “Outperform”. The rating was maintained by Piper Jaffray with “Neutral” on Friday, November 13.

DSCI Company Profile

Derma Sciences, Inc. (Derma Sciences), incorporated on November 9, 1990, is a medical device company. The Firm operates through two divisions: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. Advanced and traditional wound care products are marketed globally to acute care, extended care, home healthcare, wound and burn care clinics and physician offices.

More notable recent Derma Sciences Inc (NASDAQ:DSCI) news were published by: Businesswire.com which released: “Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced …” on July 28, 2016, also Medgadget.com with their article: “Advance Wound Dressing Market Globally Expected to Drive Growth through 2025” published on December 02, 2015, Businesswire.com published: “Derma Sciences Announces Leadership and CEO Transition” on December 21, 2015. More interesting news about Derma Sciences Inc (NASDAQ:DSCI) were released by: Reuters.com and their article: “Derma Sciences exploring sale after scrapping drug program” published on November 12, 2015 as well as Businesswire.com‘s news article titled: “Derma Sciences Names Russell Olsen President of Advanced Wound Care” with publication date: August 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>